Expression of Kl67 In ER+ PR+ HER2- & ERr- PRr- HER2- Breast Cancer Patients

Authors

  • - Md Hasanuzzaman Assistant Prof. Department of Surgical Oncology, National Institute of Cancer Research & Hospital (NICRH), Dhaka
  • Md Johirul lslam Department of Cancer Epidemiology, National Institute of Cancer Research & Hospital (NICRH), Dhaka
  • AZM Mostaque Hossain Professor Department of Surgery, Dhaka Medical College (DMC), Dhaka
  • - Md Rassell Department of Surgery, Bangabandhu Sheikh Mujib Medical University (BSMMU)
  • Md Mafizur Rahman Department of Radiation & Oncology, National Institute of ENT, Dhaka
  • Mohammad Zillur Rahman Assistant Prof. Department of Surgical Oncology, National Institute of Cancer Research & Hospital (NICRH), Dhaka
  • Md Ashraf Ul Haque Department of Surgery, Kushtia Medical College, Kushtia, Bangladesh

DOI:

https://doi.org/10.3329/jss.v20i2.43812

Keywords:

Breast cancer, Ki-67, Oestrogen and progesterone receptor status, prognosis of breast cancer

Abstract

Background: Carcinoma of the breast is one of the most common malignancies in women worldwide.

Objective: The current study was conducted to evaluate the role of Ki-67 as a prognosticmarker in two definite groups of breast cancer patients (ER+ve, PR+ve, HER-ve& triple negative)in Bangladesh perspective.

Methods: Sixty nine female breast cancer patients operated at the surgical oncology departmentof National Institute of Cancer Research & Hospital were selected by non-probabilitysampling method and operated specimens were sent for immunohistochemical study of theER, PR, Her2/neu receptors and Ki-67 protein analysis. Statistical analysis was conductedusing SPSS version 17 for Windows software. P-value 0.05 or less was considered as significant.

Result: The mean age of the patients was 46.96 years with SD of± 13.13 years. Histopathologyreports revealed that 94.2% (65/69) were suffering from duct cell carcinoma (DCC) whilelobular varieties were found in 2 cases. Majority of the patients with ER+, PR+ and Ki-67 +vestatus were between 36-50 years of age. But for Her2/neu positive cases most of patientswere above 50 years of age. In Luminal A category cancer patients 69.7% showed positiveKi-67 expression but in case of triple negative cases this percentage was 87.5%. However, thisdifference was not statistically significant.

Conclusion: Scores based upon staining of ER, PR, Her2/neu and Ki-67 collectively known asIHC4 which can be used as prognostic markers in breast cancer patients.

Journal of Surgical Sciences (2016) Vol. 20 (2) :37-41

Downloads

Download data is not yet available.
Abstract
6
PDF
6

Downloads

Published

2019-11-07

How to Cite

Md Hasanuzzaman, .-., lslam, M. J., Hossain, A. M., Md Rassell, .-., Rahman, M. M., Rahman, M. Z., & Haque, M. A. U. (2019). Expression of Kl67 In ER+ PR+ HER2- & ERr- PRr- HER2- Breast Cancer Patients. Journal of Surgical Sciences, 20(2), 37–41. https://doi.org/10.3329/jss.v20i2.43812

Issue

Vol. 20 No. 2 (2016)

Section

Original Articles

License

No part of the materials published in this Journal may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Reprints of any article in file Journal will be available from the publisher.